Drugs / mOPV2
mOPV2
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02643368 Comparator | Dec 2015 → Feb 2016 | poliomyelitis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mOPV2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02643368 ↗ |
| Known as | monovalent oral type 2 polio vaccine | “Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age” NCT02643368 ↗ |
| Known as | Monovalent Type 2 Oral Poliovirus Vaccine | “Monovalent Type 2 Oral Poliovirus Vaccine (mOPV2) and inactivated poliovirus vaccine (IPV) are used to respond to type 2 poliovirus outbreaks.” PMID 29571817 ↗ Mar 2018 |
| Modality | Vaccine | “Monovalent Type 2 Oral Poliovirus Vaccine” NCT02643368 ↗ |
| Route | Oral | “monovalent oral type 2 polio vaccine (mOPV2)” NCT02643368 ↗ |